Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00187161 · ClinicalTrials.gov registry record · Phase 2
Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL
A Phase 2 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT00187161 is a Phase 2 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 68 participants.
The verdict
NCT00187161, a Phase 2 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
This is a pilot study to demonstrate that the modified LMB-89 treatment regimen for children with newly diagnosed small noncleaved cell NHL, large cell NHL (B-cell), and B-cell acute lymphoblastic leukemia can be delivered in this setting with acceptable toxicity.
Interventions
- DRUG Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 1994-11 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00187161
The ClinicalTrials.gov registry entry for NCT00187161 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin is the first listed.
NCT00187161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00187161 about?
NCT00187161 is a clinical study titled "Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL". This is a pilot study to demonstrate that the modified LMB-89 treatment regimen for children with newly diagnosed small noncleaved cell NHL, large cell NHL (B-cell), and B-cell acute lymphoblastic leukemia can be delivered in this setting with acceptable toxicity.
What is the current status of trial NCT00187161?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 1994-11. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00187161?
The interventions under investigation include: Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin (DRUG).
Who is sponsoring clinical trial NCT00187161?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.